Bayer: will present new data at ESMO

(CercleFinance.com) - Bayer will present detailed new data from its oncology portfolio at the forthcoming European Society for Medical Oncology (ESMO) congress, to be held in Barcelona, Spain, from September 13 to 17, 2024.


Bayer will unveil late-breaking data from the ARANOTE Phase III trial in hormone-sensitive metastatic prostate cancer for darolutamide.

The Group will also present late-breaking data from the PEACE-III trial of the first and only targeted alpha therapy radium-223 dichloride approved in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer.

As part of Bayer's broader commitment to innovation in difficult-to-treat cancers, new data on larotrectinib and an update on 2927088 BAY will be presented at the congress.

Copyright (c) 2024 CercleFinance.com. All rights reserved.